8-K: OptimizeRx CCO Theresa Greco to Depart

OptimizeRx Corporation announced the departure of Chief Commercial Officer Theresa Greco, effective June 15, 2026, under a separation and advisory agreement.

Summary

• Theresa Greco will step down as Chief Commercial Officer of OptimizeRx Corporation effective June 15, 2026.
• The company entered into a Separation and Advisory Agreement on June 1, 2026, which becomes effective June 9, 2026.
• Greco will receive 12 months of base salary continuation at $380,000 per annum.
• A one-time lump sum payment of $209,000 representing her annual cash bonus target will be paid.
• The company will provide COBRA premium reimbursement for 12 months.
• Greco will serve as an advisor to the company for 12 months, through June 15, 2027, during which time her existing equity will continue to vest.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; while executive departures create uncertainty, the structured transition and non-compete protections mitigate immediate operational risk.

Positives

• The transition includes a 12-month advisory period, ensuring continuity of knowledge.
• The agreement includes non-compete and non-solicitation clauses protecting the company's talent and client base for 12 months.
• The separation terms were pre-negotiated under an existing employment agreement, minimizing legal uncertainty.

Negatives

• The departure of a Chief Commercial Officer represents a loss of executive leadership in a key revenue-generating role.
• The company incurs significant severance costs, including $380,000 in salary and a $209,000 bonus payout.

Risks

• Potential disruption to commercial operations and sales strategy following the departure of the CCO.
• Risk of failure to effectively transition commercial responsibilities during the advisory period.
• Potential for change-in-control bonus obligations if a corporate transaction occurs during the advisory term.

Future Outlook

The company expects to utilize the departing CCO as an advisor for 12 months to assist with the transition of commercial responsibilities.

Management Comments

• The company and the Chief Executive Officer will determine the advisory services to be rendered by Ms. Greco from time to time.

Industry Context

StockSavvy.ai notes that executive turnover in the health-tech sector is common, but the departure of a CCO often signals a shift in commercial strategy or a need for renewed sales momentum.

Comparison to Industry Standards

• The severance package is consistent with standard executive separation agreements for publicly traded mid-cap technology firms.
• The inclusion of a 12-month advisory period is a common practice to mitigate the impact of executive departures on institutional knowledge.

Management Changes

Corporate Governance

Legal Proceedings

• None disclosed.

Related Party Transactions

• None disclosed.

Stakeholder Impact

• Shareholders may experience short-term uncertainty regarding commercial leadership.
• Employees and clients are protected by non-solicitation agreements.

Next Steps

• Filing of the full Separation and Advisory Agreement as an exhibit to the Q2 2026 Form 10-Q.
• Transition of commercial duties to remaining leadership or a successor.

Key Dates

Recommendation

The departure of a CCO is a significant leadership change, but the structured transition and lack of negative operational news suggest a hold position until a successor is named and the commercial strategy is clarified.

Keywords

OptimizeRx, OPRX, Executive Departure, Chief Commercial Officer, Corporate Governance, Separation Agreement